Glucagon-like peptide-1 receptor agonists, often called GLP-1s, promote weight loss by helping you feel full sooner and longer. They were first used to treat type 2 diabetes, and prescriptions increased by over 700 percent between 2019 and 2023.
Now, GLP-1s are available for weight loss, but plenty of misconceptions exist about how best to use these drugs.
1. Myth: GLP-1s Are an ‘Easy Fix’ for Weight Loss
It may sound nice to think about taking GLP-1s and watching the numbers on your scale fall without making any other changes. But these medications work best when combined with a healthy diet and regular exercise.
“The scale is important, but what makes up that number is far more important,” says Matthew Fourman, MD, a bariatric surgeon in private practice in Columbus, Ohio. “These drugs do not take the place of good nutrition and exercise as part of a healthy lifestyle.”
When you take GLP-1s, a healthy diet, physical activity, plenty of quality sleep, and stress management work together to help you achieve lasting results, says Bronwyn Holmes, MD, a women’s health physician in private practice in Silicon Valley, California. Dr. Holmes advises medical providers on treatments like GLP-1s. “Weight loss becomes temporary when patients stop taking their medication, because they lack essential weight management elements,” she says.
2. Myth: Most People Have Side Effects
“One of the biggest myths people hear about GLP-1s is that most people have side effects,” says Holly Lofton, MD, an obesity medicine specialist with NYU Langone Health in New York City. Nausea, vomiting, and diarrhea are the most common GLP-1 side effects, but these symptoms aren’t inevitable.
One study review looked at GLP-1 side effects and found that only about 12 percent of people who took these medications experienced any. But side effects depend on the GLP-1 you take, and their severity can vary.
For example, two studies found that semaglutide (Ozempic, Wegovy) causes gastrointestinal symptoms like nausea more often than other types, but liraglutide (Saxenda, Victoza) causes more problems with the gallbladder and pancreas.
These side effects are most common when you first start taking a GLP-1, or when your dose gets increased, but they often improve as you take them consistently, says Dr. Lofton.
3. Myth: You Can Eat Whatever You Want While Taking a GLP-1
Sometimes people believe that their GLP-1 medication makes all food choices acceptable, says Holmes. “But GLP-1 medications produce their best results when patients consume nutrient-dense, protein-based meals while maintaining regular hydration,” she says.
Because of the decreased appetite that comes with GLP-1s, some people may not eat enough protein, leading to muscle loss. “Adequate protein intake is vital to maintaining a favorable body composition,” says Holmes. Even in a best-case scenario, where enough protein is consumed, some weight loss still comes from lean body mass (muscle and bone).
Your exact protein recommendations while taking GLP-1s will depend on your gender, weight, and daily calorie goal. But experts suggest trying for 80 to 120 grams (g) of protein per day (16 to 24 percent of your calories).
4. Myth: Doctors Don’t Know if GLP-1s Are Safe
If you think GLP-1s are too good to be true, you’re not alone. And some people worry about the safety of these medications. But Lofton says she has no qualms about prescribing them. “These medications were tested in clinical trials for safety and efficacy for many years before they came to the market,” she says.
Not only have large-scale studies shown that GLP-1s are safe, they actually improve overall longevity by addressing other health concerns like diabetes and heart disease. Some weight loss medications have been made unavailable because of side effects, says Lofton, “[but] GLP-1s remain on the market and are considered safe and effective.”
However, some companies and compounding pharmacies have created their own mixture of GLP-1s. Those aren’t regulated by the U.S. Food and Drug Administration (FDA), and so they may not be as safe as options prescribed by your healthcare provider.Also, experts don’t recommend GLP-1s during pregnancy.
5. Myth: You Can Always Take Higher Doses if the Weight Stays Put
Healthcare providers typically start GLP-1s at a low dose and increase it every four weeks until you reach your goal dose. But the dose can’t be raised indefinitely, says Dr. Fourman. Some clinicians increase the dose slower than every four weeks, with the goal of limiting side effects and helping produce sustainable lifestyle changes.
“There has to be some nuance and intelligence when it comes to managing each patient,” says Fourman. “Plateaus happen, but continually ramping up the dose in a consistent manner can lead to increased frequency of complications.”
Most people also don’t take GLP-1s long-term, and studies have only observed people taking them for a max of three to four years. Some people get off GLP-1 medicines because of side effects. Others stop taking them due to high out-of-pocket costs, lack of insurance coverage, or changes in insurance coverage.
The Takeaway
GLP-1s have helped thousands lose weight by suppressing appetite, but myths still exist around these popular medications.
Because GLP-1s can cause rapid weight loss, some people believe they can eat whatever they want, skip exercise, and boost their dose as many times as needed.
When you take GLP-1s, you need more protein in your diet, regular exercise, excellent sleep, and stress management to achieve the best, longest-lasting results.
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Mahase E. GLP-1 Agonists: Us Sees 700% Increase Over Four Years in Number of Patients Without Diabetes Starting Treatment. BMJ. July 23, 2024.
Mozaffarian D et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. The American Journal of Clinical Nutrition. July 2025.
Collins L et al. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. February 29, 2024.
Xie X et al. Comparative Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists and Multi-Target Analogs in Type 2 Diabetes: A Bayesian Network Meta-Analysis. Frontiers in Pharmacology. September 19, 2025.
Yang Q et al. Stratified Analysis of the Association Between Anti-Obesity Medications and Digestive Adverse Events: A Real-World Study Based on the FDA Adverse Event Reporting System Database. BMC Pharmacology and Toxicology. September 12, 2024.
Liu L et al. Association Between Different GLP-1 Receptor Agonists and Gastrointestinal Adverse Reactions: A Real-World Disproportionality Study Based on FDA Adverse Event Reporting System Database. Frontiers in Endocrinology. December 7, 2022.
Huang YN et al. Long-Term Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Individuals With Obesity and Without Type 2 Diabetes: A Global Retrospective Cohort Study. Diabetes, Obesity and Metabolism. August 22, 2024.
Semaglutide (Subcutaneous Route). Mayo Clinic. December 1, 2025.
Jensen SBK et al. Healthy Weight Loss Maintenance With Exercise, Glp-1 Receptor Agonist, or Both Combined Followed by One Year Without Treatment: A Post-Treatment Analysis of a Randomised Placebo-Controlled Trial. eClinicalMedicine. February 19, 2024.
Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight Management and Wellness Clinic in Aurora. Dr. Gilden works in a multidisciplinary academic center with other physicians, nurse practitioners, registered dietitians, and a psychologist, and collaborates closely with bariatric surgeons.
Gilden is very involved in education in obesity medicine, lecturing in one of the obesity medicine board review courses and serving as the lead author on the Annals of Internal Medicine article "In the Clinic" on obesity.
He lives in Denver, where he enjoys spending time with family, and playing tennis.
Abby McCoy is an experienced registered nurse who has worked with adults and pediatric patients encompassing trauma, orthopedics, home care, transplant, and case management. She is a married mother of four and loves the circus — that is her home! She has family all over the world, and loves to travel as much as possible.
McCoy has written for publications like Remedy Health Media, Sleepopolis, and Expectful. She is passionate about health education and loves using her experience and knowledge in her writing.
